Direxion Daily S&P Biotech Bear 3X ETF
LABD
17 hedge funds and large institutions have $11.3M invested in Direxion Daily S&P Biotech Bear 3X ETF in 2026 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 6 closing their positions.
84% more call options, than puts
Call options by funds: $17.3M | Put options by funds: $9.41M
0% more funds holding
Funds holding: 17 → 17 (0)
0% more ownership
Funds ownership: 16.94% → 16.94% (+0%)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
23% less capital invested
Capital invested by funds: $14.6M → $11.3M (-$3.31M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Capstone Capital Management
Hong Kong,
|
+$1.9M |
| 2 |
Squarepoint
New York
|
+$1.24M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.23M |
| 4 |
Goldman Sachs
New York
|
+$1.12M |
| 5 |
CF
Cantor Fitzgerald
New York
|
+$965K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JF
Jump Financial
Chicago,
Illinois
|
-$2.97M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$1.08M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
-$946K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$833K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$762K |
LABD Hedge Fund Activity: Q1 2026 in Review
17 of the 8,199 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bear 3X ETF (LABD) for Q1 2026, worth a combined $11.3M — down 23% from $14.6M a quarter earlier.
Fund positioning in LABD was balanced in Q1 2026: 6 funds opened new positions, 6 closed out, 5 added to existing stakes and 6 trimmed.
The largest buyer was Capstone Capital Management, opening a new position worth an estimated $1.9M. The largest seller was Jump Financial, exiting entirely with an estimated $2.97M sold.
- 17 institutional investors held Direxion Daily S&P Biotech Bear 3X ETF (LABD) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $11.3M of Direxion Daily S&P Biotech Bear 3X ETF stock for Q1 2026, down 23% quarter-over-quarter.
- 6 funds opened new Direxion Daily S&P Biotech Bear 3X ETF positions in Q1 2026 and 6 closed out, a net change of 0 holders.
- The largest Direxion Daily S&P Biotech Bear 3X ETF buyer in Q1 2026 was Capstone Capital Management, an estimated $1.9M added.
- The largest Direxion Daily S&P Biotech Bear 3X ETF seller in Q1 2026 was Jump Financial, an estimated $2.97M sold.
Based on aggregated 13F filings for Q1 2026.